Skip to main content
PYC THERAPEUTICS LIMITED logo

PYC THERAPEUTICS LIMITED — Investor Relations & Filings

Ticker · PYC ISIN · AU000000PYC7 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,297 across all filing types
Latest filing 2022-11-22 AGM Information
Country AU Australia
Listing ASX PYC

About PYC THERAPEUTICS LIMITED

https://pyctx.com/

PYC Therapeutics Limited is a clinical-stage company focused on developing precision medicines for patients with rare genetic diseases. The company utilizes a proprietary drug delivery platform that combines naturally derived cell-penetrating peptides with antisense oligonucleotides to create RNA-based therapeutics. This platform is designed to overcome the challenges of delivering large therapeutic molecules into target cells, particularly within the eye and central nervous system. PYC's primary pipeline includes VP-001, a candidate for Retinitis Pigmentosa type 11, and PYC-001, targeting Autosomal Dominant Optic Atrophy. Additionally, the company is advancing programs for Polycystic Kidney Disease. By leveraging its delivery technology, PYC aims to address the underlying genetic causes of diseases that currently lack effective treatment options.

Recent filings

Filing Released Lang Actions
2022 AGM Chairman's Address and CEO Presentation 17 pages 1.8MB
AGM Information Classification · 95% confidence The document is titled '2022 AGM Chairman’s Address and CEO Presentation' and includes a Chairman's address and a CEO presentation to be made at the 2022 Annual General Meeting (AGM). It contains forward-looking statements, company strategy, pipeline updates, and milestones, which are typical contents of presentations shared during an AGM. There is no indication that this is a full annual report or financial statement, nor is it a transcript of a call or an announcement of voting results. The document is a presentation material specifically prepared for the AGM event. Therefore, it fits the category of AGM Information (AGM-R). The document length is substantial and contains detailed presentation content, not just an announcement or a brief summary, supporting this classification with high confidence.
2022-11-22 English
Results of Annual General Meeting 2 pages 239.4KB
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled '2022 Results of Annual General Meeting' and details the outcomes of shareholder votes on various resolutions at the AGM held on 23 November 2022. It includes voting results, proxy information, and references to the Corporations Act and Listing Rule 3.13.2. The content is focused on announcing the official voting results from the AGM rather than providing the full AGM materials or presentations. The document length is 3619 characters, which is relatively short and consistent with a voting results announcement rather than a full report or presentation. Therefore, this document fits the category of 'Declaration of Voting Results & Voting Rights Announcements' (DVA).
2022-11-22 English
Annual General Meeting - Conference Call 2 pages 167.9KB
AGM Information Classification · 95% confidence The document is an announcement reminding shareholders about the upcoming Annual General Meeting (AGM) of PYC Therapeutics, including details on the date, time, location, and how to join via a conference link. It does not contain any financial data, results, or detailed meeting materials. The document is short (3526 characters) and serves as a notification or invitation rather than the AGM materials themselves. Therefore, it fits the category of AGM Information (AGM-R), which covers presentations and materials shared during the AGM or related announcements about the AGM event.
2022-11-20 English
Successful Toxicology Studies Pave Way for Human Trials 3 pages 218.7KB
Regulatory Filings Classification · 95% confidence The document is an announcement from PYC Therapeutics about the successful completion of Good Laboratory Practice (GLP) toxicology studies for their investigational drug candidate VP-001. It discusses preclinical safety results and the company's plan to submit an Investigational New Drug (IND) application to regulatory authorities to initiate human clinical trials. The content focuses on preclinical study results and regulatory submission plans rather than financial data, management changes, or shareholder information. It is not a full financial report, earnings release, or regulatory certification. The document is a corporate announcement about a scientific and regulatory milestone, which fits best under the category of Regulatory Filings (RNS) as it is a general regulatory announcement that does not fit other specific categories like Annual Report, Earnings Release, or Clinical Trial Report. The document length (8141 characters) and content confirm it is not a brief report publication announcement or a certification letter.
2022-11-06 English
Quarterly Activities/Appendix 4C Cash Flow Report 10 pages 458.5KB
Interim / Quarterly Report Classification · 95% confidence The document is titled 'REPORT FOR THE QUARTER ENDED 30 September 2022 (Q3)' and contains detailed information about the company's activities, pipeline progress, clinical trial plans, and financial update including cash on hand and cash flow statements for the quarter. It includes substantive financial data such as cash flows from operating and investing activities, remuneration paid, and expected tax incentives. The document is approximately 15,000 characters long, indicating it is a full report rather than a brief announcement. The content and structure align with a comprehensive quarterly financial report rather than a brief earnings release or announcement. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). Q3 2022
2022-10-30 English
Notification regarding unquoted securities - PYC 7 pages 30.4KB
Share Issue/Capital Change Classification · 100% confidence The document is an announcement from PYC Therapeutics Limited dated October 28, 2022, regarding the issue of unlisted options under an employee incentive scheme. It details the number and type of securities issued, their exercise price, expiry date, and confirms that these securities are not quoted on the ASX until restrictions end. The document is structured as a notification of securities issuance, referencing ASX listing rules and providing specifics about the securities issued. There is no financial performance data, management discussion, or audit information. The content aligns with announcements about share issues or capital changes rather than a full report or regulatory filing. Therefore, the document fits the category of Share Issue/Capital Change (SHA).
2022-10-27 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.